FindTrial
Sign In

Efficacy and Prognostic Value of Peripheral Blood HPV cfDNA in Cervical Cancer Immunotherapy

Efficacy and Prognostic Value of Peripheral Blood HPV cfDNA in Cervical Cancer Immunotherapy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500108111
Enrollment
Unknown
Registered
2025-08-25
Start date
2025-09-01
Completion date
Unknown
Last updated
2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical cancer

Interventions

Advanced cervical cancer received immunotherapy group:Immunotherapy

Sponsors

West China Second University Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Be aged 18 years or older (including 18) and 75 years or younger (including 75) at the time of signing the informed consent form; 2. Pathologically confirmed HPV-positive advanced cervical cancer patients; 3. Have never received immunotherapy; 4. Able to provide blood samples at each monitoring time point during the peri-treatment and follow-up periods for testing; 5. Complete radiotherapy, chemotherapy, and immunotherapy as planned.

Exclusion criteria

Exclusion criteria: 1. Having received immunotherapy previously; 2. Unable to undergo enhanced MRI or enhanced CT for clinical follow-up; 3. Unable to obtain complete clinicopathological data and follow-up information; 4. Other circumstances where the researcher deems that the subject should not participate in this study.

Design outcomes

Primary

MeasureTime frame
HPV cfDNA in peripheral blood;—

Countries

China

Contacts

Public ContactLifei Sun

West China Second University Hospital

sun-lifei@foxmail.com+86 182 8644 6081

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026